Market research
0TB.F Theravance Biopharma, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 758M
- P/E ratio
- 16.4
- Analyst target
- 9.38
- Dividend yield
- Not available
- Beta
- 0.25
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KYG8807B1068
- Market cap
- 758M
- P/E ratio
- 16.4
- Analyst target
- 9.38
- Dividend yield
- Not available
- Beta
- 0.25
About
About Theravance Biopharma, Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0TB.F discussion.
5 years, 4 months ago
Theravance Biopharma, Inc is currently in a long term downtrend where the price is trading 23.2% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.6.
Theravance Biopharma, Inc's total revenue sank by 36.5% to $19M since the same quarter in the previous year.
Its net income has increased by 10.9% to $-58M since the same quarter in the previous year.
Finally, its free cash flow fell by 0.8% to $-66M since the same quarter in the previous year.
Based on the above factors, Theravance Biopharma, Inc gets an overall score of 2/5.